Cite
HARVARD Citation
Bachet, J. et al. (2015). A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial. BMC cancer. 15 (1), pp. 1-11. [Online].